How does PD-L1 impact treatment options for lung cancer?


Dr. Edward Garon explains the role of a patient’s PD-L1 levels in lung cancer treatment decision making. PD-L1 is an important biomarker that can help physicians decide whether or not a patient may be eligible for immunotherapy. Learn more at Lung.org/pdl1

Support for this educational program provided by Amgen, AstraZeneca, Blueprint Medicines, Bristol Myers Squibb, Genentech, Lilly Oncology, Merck, Novartis and Pfizer.

source

Leave a Reply

Your email address will not be published.